Lupin Limited has informed the Exchange regarding a press release dated December 04, 2025, titled "Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg (Pegfilgrastim-unne) in the United States".
Press Release Dec 04 2025
Filed with NSE · · 3 pages · English
Release
Earlier from Lupin
- Press Release Dec 01 2025
- Press Release Nov 28 2025
- Press Release Nov 15 2025
- Press Release Nov 14 2025
- Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
Later from Lupin
- Press Release Dec 05 2025
- Press Release Dec 12 2025
- Lupin Limited Press Release Dec 16 2025
- Press Release Dec 17 2025
- Press Release Dec 18 2025
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin